Source-grounded facts extracted from Phio Pharmaceuticals Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Phio Pharmaceuticals Corp. reported quarter ended March 31, 2026 results: net income $4.0 million.
“31, 2025. The increase in general and administrative expenses was primarily driven by employee related costs, investor outreach and professional fees. Net Loss Net loss was $ 4.0 million for the three months ended March 31, 2026 as compared with $1.8 million for the three months ended March 31, 2025. The increase in net loss was attributable to increases in”
Phio Pharmaceuticals Corp. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at $6,360,000 (effective 2026-04-08).
“On April 8, 2026, Phio Pharmaceuticals Corp. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.0001 per share (the “Shares”). The offering and sale of up to $6,360,000 of the Shares pursuant to the Sales Agreement is being registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279557), which was declared effective by the Securities and Exchange Commission (“SEC”) on July 1, 2024, which includes a base prospectus, and an accompanying prospectus supplement filed with the SEC on April 8, 2026.”
Phio Pharmaceuticals Corp. issued up to 424,739 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for services as placement agent.
“Additionally, in connection with the above-mentioned offering, the Company agreed to issue to Wainwright or its designees as compensation, warrants to purchase up to an aggregate of 424,739 shares of Common Stock, equal to 7.5% of the aggregate number of Existing Warrants exercised in the offering (the “Placement Agent Warrants”) and, if the New Warrants are exercised for cash in the future, further warrants to purchase shares of Common Stock equal to the 7.5% of the aggregate number of New Warrants so exercised.”
Phio Pharmaceuticals Corp. issued up to 11,326,364 shares of Common Stock of warrant to holders of existing common stock warrants for exercise of existing warrants for cash and payment of $0.125 per New Warrant, aggregate $1,415,795.50.
“In consideration for the exercise of such warrants for cash and the payment of an additional $0.125 per New Warrant (as defined below), or an aggregate of $1,415,795.50 for all New Warrants, the Company agreed to issue to the Holders new unregistered Series A Warrants (the “New Warrants”) to purchase an aggregate of up to 11,326,364 shares of Common Stock (the “New Warrant Shares”).”
Robert Infarinato was appointed as VP, Strategic Development at Phio Pharmaceuticals Corp..
“Also effective June 6, 2025, Mr. Infarinato, who was previously the Company’s Chief Financial Officer, now serves as VP, Strategic Development of the Company.”
Lisa Carson was appointed as VP, Finance and Administration at Phio Pharmaceuticals Corp..
“designated Lisa Carson, VP, Finance and Administration of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of June 6, 2025.”
Phio Pharmaceuticals Corp. engaged Grant Thornton LLP as its auditor.
“Also on April 17, 2025, the Audit Committee approved the engagement of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.”
Phio Pharmaceuticals Corp. dismissed BDO USA, P.C. as its auditor.
“on April 17, 2025, the Audit Committee approved the dismissal of BDO USA, P.C. ("BDO") as the Company's independent registered public accounting firm, effective immediately.”
David H. Deming was appointed as Director at Phio Pharmaceuticals Corp..
“Effective as of February 19, 2025, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed Mr. David H. Deming to serve on the Board until the 2025 annual meeting of stockholders.”
Caitlin Kontulis departed as Vice President of Finance and Administration and Secretary at Phio Pharmaceuticals Corp..
“Caitlin Kontulis, Vice President of Finance and Administration and Secretary of the Company, ceased serving as the Company’s principal accounting officer, effective as of August 1, 2024, with her employment terminating on August 31, 2024.”
Robert M. Infarinato was appointed as Vice President, Chief Financial Officer at Phio Pharmaceuticals Corp..
“On July 15, 2024, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert M. Infarinato to serve as the Company’s Vice President, Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of August 1, 2024.”
Phio Pharmaceuticals Corp. entered into Purchase Agreement with Triton Funds LP valued at $621,000 (effective 2024-05-16).
“On May 16, 2024, Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Triton Funds LP (“Triton”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 862,500 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $621,000.”
Phio Pharmaceuticals Corp. reported the three months ended March 31, 2024 results: net income Net loss was $2.2 million for the three months ended March 31, 2024.
“On May 9, 2024, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended March 31, 2024.”
Phio Pharmaceuticals Corp. reported the year ended December 31, 2023 results: net income $10.8 million, EPS $5.20 per share.
“Net loss was $10.8 million, or $5.20 per share, for the year ended December 31, 2023”
Phio Pharmaceuticals Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 24, 2024, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Capital Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock The Notification Letter provides an initial 180 calendar day period, or until July 22, 2024, in which to reg”
Phio Pharmaceuticals Corp. entered into Inducement Letter Agreement with certain holders valued at approximately $2.8 million (effective 2023-12-06).
“On December 6, 2023, Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), entered into an inducement letter agreement (the “Inducement Letter Agreement”) with certain holders (the “Holders”) of certain of its existing warrants to purchase up to an aggregate of 2,130,252 shares of the Company’s common stock”
Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2023 results: net income Net loss was $2.8 million, or $1.14 per share.
“Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended September 30, 2023.”
Phio Pharmaceuticals Corp. reported quarter ended June 30, 2023 results: net income $2.5 million, or $1.47 per share.
“Net loss was $2.5 million, or $1.47 per share, for the quarter ended June 30, 2023”
Phio Pharmaceuticals Corp. shareholders approved Amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares by 125,500 at the 2023-07-20 meeting.
“Proposal 3: Amendment and Restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan For Against Abstain Broker Non-Votes 98,254 44,696 1,139 486,011”
Phio Pharmaceuticals Corp. shareholders approved Ratification of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-07-20 meeting.
“Proposal 2: Ratification of Auditors For Against Abstain 605,026 21,903 3,171”
Phio Pharmaceuticals Corp. shareholders approved Election of five directors to serve until the 2024 Annual Meeting at the 2023-07-20 meeting.
“Nominee For Withheld Broker Non-Votes Robert J. Bitterman 126,094 17,995 486,011”
Phio Pharmaceuticals Corp. entered into Engagement Letter with H.C. Wainwright & Co., LLC with H.C. Wainwright & Co., LLC valued at Cash fee of 7.5% of gross proceeds; management fee of 1.0%; $60,000 for non-accountable expenses; $1 (effective 2023-01-20).
“Pursuant to an engagement letter, dated as of January 20, 2023 (the “Engagement Letter”), between the Company and H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent a total cash fee equal to 7.5% of the gross proceeds received in the Registered Direct Offering and the PIPE Private Placement.”
Phio Pharmaceuticals Corp. entered into PIPE Purchase Agreement with same institutional and accredited investors valued at 72,000 unregistered shares of common stock at $4.28 per share; pre-funded warrants; Series A and B w (effective 2023-05-31).
“On May 31, 2023, the Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement” and, together with the Registered Direct Purchase Agreement, the “Purchase Agreements”) and a registration rights agreement (the “Registration Rights Agreement”) with the same institutional and accredited investors in connection with a concurrent private placement (the “PIPE Private Placement”).”
Phio Pharmaceuticals Corp. entered into Registered Direct Purchase Agreement with certain institutional and accredited investors valued at 233,646 shares of common stock at $4.28 per share; RD Series A and B warrants (effective 2023-05-31).
“On May 31, 2023, Phio Pharmaceuticals Corp. (the “Company”) entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) with certain institutional and accredited investors in connection with a registered direct offering (the “Registered Direct Offering”).”
Phio Pharmaceuticals Corp. reported the quarter ended March 31, 2023 results: net income Net loss increased 36% to approximately $3.6 million, EPS $3.15 per share.
“Net loss increased 36% to approximately $3.6 million, or $3.15 per share, for the quarter ended March 31, 2023”
Phio Pharmaceuticals Corp. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-01-20).
“Pursuant to an engagement letter, dated as of January 20, 2023 (the “Engagement Letter”), between the Company and H.C. Wainwright & Co., LLC, or the placement agent”
Phio Pharmaceuticals Corp. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.65 million (effective 2023-04-18).
“On April 18, 2023, Phio Pharmaceuticals Corp. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 353,983 shares of the Company’s common stock”
Phio Pharmaceuticals Corp. reported the year ended December 31, 2022 results: net income approximately $11.5 million, or $10.10 per share, EPS $10.10 per share.
“Net loss decreased 14% to approximately $11.5 million, or $10.10 per share, for the year ended December 31, 2022, compared with $13.3 million, or $12.43 per share, for the year ended December 31, 2021.”
Robert J. Bitterman was appointed as President and Chief Executive Officer and Chair of the Board at Phio Pharmaceuticals Corp..
“On February 17, 2023, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert J. Bitterman, acting Executive Chairman of the Board and acting Interim Chief Executive Officer, to serve as the Company’s President and Chief Executive Officer and Chair of the Board, effective as of February 20, 2023.”
Phio Pharmaceuticals Corp.: Filed a Certificate of Amendment to effect a 1-for-12 reverse stock split of common stock (effective 2023-01-26).
“thereafter, on January 24, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-12 reverse split of its common stock (the “Reverse Stock Split”).”
Phio Pharmaceuticals Corp. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25 at the 2023-01-04 meeting.
“The Reverse Stock Split Proposal submitted to a vote of the Company’s stockholders at the Special Meeting was approved.”
Phio Pharmaceuticals Corp.: Filed Certificate of Designation designating rights, preferences, privileges and restrictions of Preferred Stock, effective November 16, 2022 (effective 2022-11-16).
“On November 16, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Preferred Stock.”
Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2022 results: net income approximately $3.6 million, or $0.26 per share, EPS $0.26 per share.
“Net loss decreased 4% to approximately $3.6 million, or $0.26 per share, for the quarter ended September 30, 2022, compared with $3.7 million, or $0.28 per share, for the quarter ended September 30, 2021.”
Geert Cauwenbergh changed role as Independent Director at Phio Pharmaceuticals Corp..
“Dr. Geert Cauwenbergh, a member of the Company’s Board, will no longer serve as the Company’s interim principal executive officer and interim principal financial officer, which positions he held since May 4, 2022.”
Robert J. Bitterman was appointed as Interim Executive Chairman at Phio Pharmaceuticals Corp..
“approved the appointment of Robert J. Bitterman, Chairman of the Company’s Board, to serve as the Company’s interim Executive Chairman, effective immediately.”
Geert Cauwenbergh was appointed as Principal Executive and Financial Officer at Phio Pharmaceuticals Corp..
“On May 4, 2022, the Board appointed Geert Cauwenbergh, Dr. Med. Sc., as the Company’s interim principal executive and financial officer, effective as of May 5, 2022.”
Gerrit Dispersyn departed as President and Chief Executive Officer at Phio Pharmaceuticals Corp..
“On May 5, 2022, Phio Pharmaceuticals Corp. (the “Company”) announced the departure of Gerrit Dispersyn, Dr. Med. Sc., from his role as President and Chief Executive Officer of the Company, effective as of May 5, 2022”
Patricia A. Bradford was appointed as Director at Phio Pharmaceuticals Corp..
“Effective as of April 27, 2022, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to eight members and appointed Patricia A. Bradford, former Senior Vice President Global Human Resources, Unisys Corporation, to serve on the Board until the 2022 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.